JP2025516648A - Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 - Google Patents

Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 Download PDF

Info

Publication number
JP2025516648A
JP2025516648A JP2024566589A JP2024566589A JP2025516648A JP 2025516648 A JP2025516648 A JP 2025516648A JP 2024566589 A JP2024566589 A JP 2024566589A JP 2024566589 A JP2024566589 A JP 2024566589A JP 2025516648 A JP2025516648 A JP 2025516648A
Authority
JP
Japan
Prior art keywords
mutant
use according
lsd1 inhibitor
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516648A5 (enExample
Inventor
ソリバ・ソリバ，ロベルト
サシロット，ナタリア
マスカーロ・クルサット，クリスティナ
ロトラント・ポソ，ダビド
Original Assignee
オリゾン・ゲノミクス・ソシエダッド・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリゾン・ゲノミクス・ソシエダッド・アノニマ filed Critical オリゾン・ゲノミクス・ソシエダッド・アノニマ
Publication of JP2025516648A publication Critical patent/JP2025516648A/ja
Publication of JP2025516648A5 publication Critical patent/JP2025516648A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024566589A 2022-05-09 2023-05-09 Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 Pending JP2025516648A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22382444 2022-05-09
EP22382443 2022-05-09
EP22382444.2 2022-05-09
EP22382443.4 2022-05-09
PCT/EP2023/062283 WO2023217784A1 (en) 2022-05-09 2023-05-09 Methods of treating nf1-mutant tumors using lsd1 inhibitors

Publications (2)

Publication Number Publication Date
JP2025516648A true JP2025516648A (ja) 2025-05-30
JP2025516648A5 JP2025516648A5 (enExample) 2026-05-19

Family

ID=86558792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566589A Pending JP2025516648A (ja) 2022-05-09 2023-05-09 Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法

Country Status (5)

Country Link
US (1) US20250295660A1 (enExample)
EP (1) EP4522137A1 (enExample)
JP (1) JP2025516648A (enExample)
CN (1) CN119497613A (enExample)
WO (1) WO2023217784A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120154611B (zh) * 2025-04-28 2025-11-18 西安交通大学医学院第一附属医院 阿昔替尼在制备丛状神经纤维瘤治疗药物中的应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010143582A1 (ja) 2009-06-11 2010-12-16 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びlsd1阻害剤
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
AU2011244478B2 (en) 2010-04-20 2014-07-17 Fondazione IEO-CCM Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2
SI2598482T1 (sl) 2010-07-29 2018-09-28 Oryzon Genomics, S.A. Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
CA2831143C (en) 2011-03-25 2019-05-21 Glaxosmithkline Intellectual Property Development Limited Cyclopropylamines as lsd1 inhibitors
UA114406C2 (uk) 2011-08-09 2017-06-12 Такеда Фармасьютікал Компані Лімітед Похідні циклопропанаміну як інгібітори lsd1
SG2014009609A (en) 2011-08-15 2014-05-29 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
RS58475B1 (sr) 2011-10-20 2019-04-30 Oryzon Genomics Sa Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori
US9751885B2 (en) 2012-10-12 2017-09-05 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
EP2927212A4 (en) 2012-11-28 2016-06-08 Univ Kyoto LSD1-SELECTIVE HEMMER WITH LYSINE STRUCTURE
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
US9918983B2 (en) 2013-05-30 2018-03-20 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells
KR102288648B1 (ko) 2013-06-19 2021-08-12 유니버시티 오브 유타 리서치 파운데이션 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체
CN103319466B (zh) 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用
AU2014306149B2 (en) 2013-08-06 2019-09-19 Imago Biosciences Inc. KDM1A inhibitors for the treatment of disease
WO2015031564A2 (en) 2013-08-30 2015-03-05 University Of Utah Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
PL3080100T3 (pl) 2013-12-11 2023-03-06 Celgene Quanticel Research, Inc. Inhibitory lizyno-specyficznej demetylazy-1
US10118903B2 (en) 2014-02-07 2018-11-06 Musc Foundation For Research Development Aminotriazole-based KDM1A inhibitors as epigenetic modulators
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
HUE057895T2 (hu) 2014-05-01 2022-06-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibitorai
AU2015265820C1 (en) 2014-05-30 2020-01-16 Ieo - Istituto Europeo Di Oncologia S.R.L. Cyclopropylamine compounds as histone demethylase inhibitors
MX376632B (es) 2014-06-27 2025-03-07 Celgene Quanticel Res Inc Inhibidores de demetilasa-1 especifica de lisina.
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
EA033698B1 (ru) 2014-07-03 2019-11-18 Celgene Quanticel Res Inc Ингибиторы лизинспецифической деметилазы-1
MX391865B (es) 2014-07-03 2025-03-21 Celgene Quanticel Res Inc Inhibidores de demetilasa-1 especifica de lisina.
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
ES2935114T3 (es) 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
KR102626978B1 (ko) 2015-02-12 2024-01-18 이마고 바이오사이언시즈 인코포레이티드 질환 치료를 위한 kdm1a 저해제
CN106146361A (zh) 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
CN106045862B (zh) 2015-04-10 2019-04-23 上海迪诺医药科技有限公司 环丙胺类螺(杂)环化合物、其药物组合物及应用
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
US20170001970A1 (en) 2015-07-02 2017-01-05 University Of Utah Research Foundation Substituted benzohydrazide analogs as histone demethylase inhibitors
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Ｌｓｄ１阻害剤の塩
CN105233292B (zh) * 2015-10-19 2018-03-13 中国科学院北京基因组研究所 Ory‑1001联合放疗和化疗用于治疗人三阴性乳腺癌的用途
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
RS61404B1 (sr) 2015-11-05 2021-02-26 Celgene Quanticel Research Inc Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primena u lečenju kancera
CA3006434C (en) 2015-11-27 2021-03-16 Taiho Pharmaceutical Co., Ltd. Biphenyl compound or salt thereof
WO2017109061A1 (en) 2015-12-23 2017-06-29 Ieo - Istituto Europeo Di Oncologia S.R.L. Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN105541806A (zh) 2015-12-25 2016-05-04 中国药科大学 巴比妥酸类化合物、制备方法及其应用
SG11201805645QA (en) 2015-12-29 2018-07-30 Mirati Therapeutics Inc Lsd1 inhibitors
CN105924362B (zh) 2016-02-05 2018-08-17 上海龙翔生物医药开发有限公司 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
CN110267945A (zh) 2016-03-01 2019-09-20 诺华股份有限公司 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
CN107174584B (zh) 2016-03-12 2020-09-01 福建金乐医药科技有限公司 含哌嗪结构化合物在制备lsd1抑制剂中的应用
CN107200706A (zh) 2016-03-16 2017-09-26 中国科学院上海药物研究所 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
US20170283397A1 (en) 2016-03-31 2017-10-05 University Of Utah Research Foundation Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
SI3455204T1 (sl) 2016-05-09 2026-03-31 Jubilant Epicore LLC Ciklopropil-amidne spojine kot dvojni zaviralci lsd1/hdac
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
CN106045881B (zh) 2016-05-26 2017-10-31 新乡医学院 一类白藜芦醇衍生物、其制备方法及作为lsd1抑制剂的应用
CN107459476B (zh) 2016-06-03 2022-06-24 中国科学院上海药物研究所 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
US11390590B2 (en) 2016-08-16 2022-07-19 Imago Biosciences, Inc. Methods and processes for the preparation of KDM1A inhibitors
CN106478639B (zh) 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432248B (zh) 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
MD3532459T2 (ro) 2016-10-26 2024-06-30 Constellation Pharmaceuticals Inc Inhibitori ai LSD1 și utilizările medicale ale acestora
WO2018081342A1 (en) 2016-10-26 2018-05-03 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
JP7217712B2 (ja) 2017-01-24 2023-02-03 シーエスピーシー ジョォンチィ ファーマシューティカル テクノロジー （シージアジョァン）カンパニー，リミテッド Ｌｓｄ１阻害剤、その製造方法及び応用
CN108530302A (zh) 2017-03-06 2018-09-14 华东师范大学 2`,3`-二氢螺[环丙烷-1,1`-茚]-2-胺衍生物及其制备方法和应用
CN106831489B (zh) 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
CN107033148B (zh) 2017-05-03 2018-10-26 郑州大学 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用
CN106928235A (zh) 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
AU2018269947B2 (en) 2017-05-15 2021-10-14 The Regents Of The University Of Michigan Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
CN110740991B (zh) 2017-05-26 2023-07-04 大鹏药品工业株式会社 新型联苯化合物或其盐
KR20180134675A (ko) 2017-06-09 2018-12-19 한미약품 주식회사 시클로프로필아민 유도체 화합물 및 이의 용도
UY37774A (es) 2017-06-19 2019-01-31 Novartis Ag Compuestos 5-cianoindol sustituidos y usos de los mismos
JP2020152641A (ja) 2017-07-07 2020-09-24 国立研究開発法人理化学研究所 リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
ES2986559T3 (es) 2017-08-18 2024-11-11 St Europeo Di Oncologia S R L Derivados de indol como inhibidores de la histona desmetilasa
CN107501169B (zh) 2017-08-25 2020-03-27 新乡医学院 一类反式二芳基乙烯类lsd1抑制剂、其制备方法及应用
CN107474011B (zh) 2017-08-25 2020-03-27 新乡医学院 一类2-苯基-4-苯乙烯基吡啶类lsd1抑制剂、其制备方法及应用
AR112900A1 (es) 2017-09-13 2019-12-26 Hanmi Pharm Ind Co Ltd Compuesto derivado de pirazol y uso de este
CN109535019B (zh) 2017-09-21 2021-08-20 华东师范大学 1,1a,6,6a-四氢环丙并[a]茚-1-胺衍生物及其制备方法与应用
KR20190040763A (ko) 2017-10-11 2019-04-19 한미약품 주식회사 피라졸로피리딘 유도체 화합물 및 이의 용도
KR20190040783A (ko) 2017-10-11 2019-04-19 한미약품 주식회사 라이신 특이적 데메틸라제-1 억제제로서의 피라졸 유도체
CN107936022A (zh) 2017-11-30 2018-04-20 郑州大学 黄嘌呤类lsd1抑制剂及其制备方法和应用
CN110204551B (zh) 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类含环丙胺结构的噻吩并[3,2-d]嘧啶衍生物、其制备方法与用途
US20210228490A1 (en) 2018-05-04 2021-07-29 Oryzon Genomics, S.A. Stable pharmaceutical formulation
KR102684364B1 (ko) 2018-05-11 2024-07-11 이마고 바이오사이언시즈 인코포레이티드 질환의 치료를 위한 kdm1a 저해제
US11944614B2 (en) 2018-05-15 2024-04-02 Regents Of The University Of Michigan Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
WO2020015745A1 (zh) 2018-07-20 2020-01-23 南京明德新药研发有限公司 一种lsd1抑制剂的盐及其晶型
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN112672994B (zh) 2018-09-13 2022-09-13 南昌弘益药业有限公司 作为lsd1抑制剂的杂螺环类化合物及其应用
US11649245B2 (en) 2018-09-13 2023-05-16 Helioeast Pharmaceutical Co., Ltd. Cyclopropylamine compound as LSD1 inhibitor and use thereof
CN109265462B (zh) 2018-10-31 2020-06-02 郑州大学 嘧啶并1,2,4-三氮唑类化合物及其制备方法和应用
CN109293664B (zh) 2018-11-14 2020-06-02 郑州大学 嘧啶并1,2,4-三氮唑肼类化合物及其制备方法和应用
JPWO2020138398A1 (ja) 2018-12-28 2021-11-04 国立研究開発法人理化学研究所 リジン特異的脱メチル化酵素１を阻害する新規化合物、その製造方法及びその用途
WO2020159285A1 (ko) 2019-02-01 2020-08-06 한미약품 주식회사 이미다조피리딘 유도체 화합물 및 이의 용도
EP3907225A4 (en) 2019-02-01 2022-09-14 Hanmi Pharm. Co., Ltd. COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE
CN112110936B (zh) 2019-06-20 2021-12-07 沈阳药科大学 四氢喹啉类衍生物及其制备方法和应用
CN110478352A (zh) 2019-08-30 2019-11-22 郑州大学 含三唑基的5-氰基-6-苯基-嘧啶类化合物在抑制lsd1中的应用及lsd1抑制剂
WO2021058024A1 (zh) 2019-09-29 2021-04-01 南京明德新药研发有限公司 Lsd1抑制剂
WO2021095840A1 (en) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS
CN111072610B (zh) 2019-12-16 2022-08-30 杭州师范大学 一类取代的苯并呋喃2-甲酰腙类lsd1抑制剂的制备和应用
CN113354622B (zh) 2020-03-06 2022-11-01 沈阳药科大学 对苯二胺类lsd1抑制剂及其制备方法
CN111454252B (zh) 2020-05-13 2021-06-11 郑州大学 含芳环/芳杂环-三氮唑-亚甲基-tcp衍生物及其制备方法和应用
CN114105950B (zh) 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
KR20230079151A (ko) 2020-10-01 2023-06-05 이마고 바이오사이언시즈 인코포레이티드 Kdm1a 에 의해 매개되는 질환 치료용 약학 제형
CN112409310B (zh) 2020-12-18 2023-04-21 许昌学院 一种具有lsd1抑制活性的化合物、制备方法及应用
CN114805261B (zh) 2021-01-18 2023-03-21 沈阳药科大学 苯并呋喃类lsd1抑制剂及其制备方法
CN112920130B (zh) 2021-02-01 2023-03-17 河北康泰药业有限公司 一种三氮唑的化合物、制备方法以及其在制备防治癌症药物中的应用
CN115485282B (zh) 2021-02-09 2025-09-09 南昌弘益药业有限公司 一种氧氮杂螺环化合物、其盐型及其晶型
WO2022188709A1 (zh) 2021-03-11 2022-09-15 南京明德新药研发有限公司 噻吩类化合物及其应用
CN113105479B (zh) 2021-04-12 2022-07-01 郑州大学 胶霉毒素6-芳香环羧酸酯系列衍生物及其制备方法
CN113087712B (zh) 2021-04-12 2022-02-22 郑州大学 L-氨基酸-6-胶霉毒素酯三氟乙酸盐及其制备方法
CN117769540A (zh) 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式
CN113264903A (zh) 2021-05-27 2021-08-17 郑州大学 一种吩噻嗪类化合物及其制备方法和应用
CN116888122A (zh) 2021-06-22 2023-10-13 南昌弘益药业有限公司 含氮氧杂螺环类化合物及其应用
WO2023284651A1 (zh) 2021-07-12 2023-01-19 南京明德新药研发有限公司 N-(2-氨基苯基)苯甲酰胺类化合物及其应用
CN113599380A (zh) 2021-08-24 2021-11-05 郑州大学 小檗碱类化合物在制备抗肿瘤药物中的应用
CN113582906B (zh) 2021-08-24 2023-05-16 郑州大学 二氟苯环丙胺类化合物及其制备方法和应用
US20250032454A1 (en) 2021-10-18 2025-01-30 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease
CN114805205A (zh) 2022-04-27 2022-07-29 郑州大学 一种吖啶类化合物及其制备方法和应用

Also Published As

Publication number Publication date
WO2023217784A1 (en) 2023-11-16
CN119497613A (zh) 2025-02-21
US20250295660A1 (en) 2025-09-25
EP4522137A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
EP3515446B1 (en) Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
AU2013203637B2 (en) Combination therapy for proliferative disorders
JP2023145467A (ja) 組み合わせ療法
JP6768682B2 (ja) メラノーマの処置に使用するためのアピリモド
CA2725390C (en) Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
US10350207B2 (en) PAC-1 combination therapy
JP2025516647A (ja) Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
CN119497613A (zh) 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
US20160220576A1 (en) Isoxazole compound for the treatment of cancer
US20250073232A1 (en) Combinations of lsd1 inhibitors for treating myeloid cancers
US20230129787A1 (en) Methods for treating ovarian cancer
JP2025538876A (ja) がん治療のためのｌｓｄ１阻害薬とメニン阻害薬の組合せ
CN117769413A (zh) 用于治疗髓样癌的lsd1抑制剂的组合
HK40004186A (en) Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
HK40004186B (en) Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
BR112019005046B1 (pt) Combinação farmacêutica, seu uso, composição farmacêutica, usos de um inibidor de craf e de um inibidor de erk, e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260511